CG Oncology, Inc. (CGON)

Price$72.00Cached quoteAs of 2026-09-11 02:10 UTC

AI: Overvalued

Price checkThe market price already assumes major clinical success, approval, and a strong commercial launch.

Using the last reported 88.3 million June shares and the observed quote, market value is at least about $6.6 billion; later share sales could make it higher. June cash and short-term investments totaled $1.03 billion, with only $3 million of debt, so roughly $5.5 billion is assigned to the drug pipeline and future business. If an investor demanded a 12% yearly return with no long-run growth, that pipeline value would need about $665 million of annual free cash flow—cash left after running and investing—if available today. Approval delays and clinical risk raise that bar, leaving too little margin of safety.

Big pictureCG Oncology has ample funding, but it still loses substantial cash before product approval.

CG Oncology remains a loss-making development company. Net loss widened from $88.0 million in 2024 to $161.0 million in 2025, while operating cash use rose from $78.7 million to $132.3 million. In the first half of 2026, net loss reached $139.3 million and operating cash use was about $103.4 million. Research spending was $116.6 million in 2025 and about $98.4 million in the first half of 2026. There are no dividends or buybacks. This is not a normal economic-cycle business; trial results, approval timing, and share issuance drive value far more than recessions or expansions.

Business strengthStrong late-stage data and a cash-heavy balance sheet give the drug program real staying power.

The balance sheet provides real protection against near-term funding stress: June cash plus short-term investments were about $1.03 billion, versus $56.5 million of total liabilities. The lead drug also has unusually mature evidence for a pre-approval biotech. In BOND-003 Cohort C, 75.5% achieved a complete response, meaning no detectable cancer by the study’s criteria; median response duration was at least 27.9 months, about 81% kept their bladder at 24 months, and only 3.4% progressed to muscle-invasive disease. No severe treatment-related events were reported. Those results support the bull case, but they still do not equal approval or commercial demand.

What could change the storyUpcoming trial results and regulatory steps can justify the premium or expose too much optimism.

The biggest near-term swing factor is the Phase 3 PIVOT-006 result in intermediate-risk bladder cancer, followed by planned completion of the initial approval application in the fourth quarter of 2026. Strong randomized data and a smooth filing could justify part of today’s pipeline premium by expanding the reachable patient pool. Weak data, another timeline slip, or regulatory friction would challenge it. Dilution also matters: shares rose from 76.2 million at the end of 2024 to 88.3 million by June 2026, and the company added another $500 million of possible stock sales in August.

AI: News

BOND-003 journal validationPublished Phase 3 results strengthened the case that cretostimogene can deliver durable bladder-sparing responses.

On July 27, 2026, The Lancet Oncology publication reported a 75.5% complete-response rate at any time in BOND-003 Cohort C, with median response duration of at least 27.9 months. About 89% of patients kept their bladder at 12 months and 81% at 24 months; 3.4% progressed to muscle-invasive disease. The announcement came after the market close; shares fell about 1% the next session, so the muted reaction cannot be cleanly attributed to this news. The data support the planned approval filing in high-risk disease.

Q2 runway updateThe company showed enough liquid funding to pursue approval and launch preparation without near-term financing pressure.

On August 6, 2026, CG Oncology reported about $1.03 billion of cash and short-term investments and said that should fund operations through 2029. First-half operating cash use was about $103 million, so the cushion is substantial even as research spending rises. Management also said PIVOT-006 Phase 3 results were expected near term and the initial approval application remained planned for the fourth quarter. Shares gained about 3% that session, but several same-day disclosures make attribution uncertain.

Stock-sale capacity expandedManagement created room to sell much more stock, improving funding flexibility but increasing dilution risk.

Also on August 6, the company increased its stock-sale program from $550 million to $1.05 billion after already selling about 10.8 million shares for $550 million of gross proceeds. The program lets CG Oncology issue new shares into the market over time. At the filing’s reference price, the extra $500 million capacity represented about 6.9 million more shares, roughly 8% of June shares outstanding. That improves funding flexibility without much debt, but using it would spread future business value across more shares.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

2022

2024

2025

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$4.0M	$1.1M	$204,000	$191,000
Research & development	$116.6M	$82.1M	$45.8M	$29.0M
Operating expenses	$194.8M	$115.8M	$55.7M	$35.4M
Operating income	−$190.8M	−$114.7M	−$55.4M	−$35.2M
Operating margin	−4,722.13%	−10,067.25%	−27,180.88%	−18,453.40%
EBITDA	−$189.3M	−$114.6M	−$55.4M	−$35.2M
EBITDA margin	−4,686.36%	−10,064.44%	−27,172.55%	−18,445.55%
Net income	−$161.0M	−$88.0M	−$48.6M	−$35.4M
Net profit margin	−3,985.02%	−7,729.50%	−23,826.96%	−18,556.54%
Basic EPSper basic share	-$2.08	-$1.41	-$15.65	-$11.71
Diluted EPSper diluted share	-$2.08	-$1.41	-$15.65	-$11.71

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

9.64%of listed shares

RTW INVESTMENTS, LP8.51M shares · Jun 30, 2026

View holders

Top 20 reported holders of CGON
Holder	% owned
RTW INVESTMENTS, LP	9.64%8.51M shares
Song Hong Fang	≈7.97%7.04M shares
T. Rowe Price Investment Management, Inc.	7.49%6.62M shares
Decheng Capital LLC	7.22%6.37M shares
BlackRock, Inc.	7.08%6.26M shares
WELLINGTON MANAGEMENT GROUP LLP	6.03%5.32M shares
FMR LLC	4.71%4.16M shares
PRICE T ROWE ASSOCIATES INC /MD/	4.31%3.81M shares
TCG Crossover Management, LLC	4.16%3.67M shares
VANGUARD PORTFOLIO MANAGEMENT LLC	3.92%3.47M shares
STATE STREET CORP	3.89%3.44M shares
VANGUARD CAPITAL MANAGEMENT LLC	3.76%3.32M shares
Foresite Capital Management VI LLC	2.68%2.37M shares
GEODE CAPITAL MANAGEMENT, LLC	2.44%2.15M shares
Liu Brian Guan-Chyun	≈2.14%1.89M shares
Seven Fleet Capital Management LP	2.14%1.89M shares
EcoR1 Capital, LLC	1.69%1.49M shares
DV Trading LLC	1.63%1.44M shares
Avidity Partners Management LP	1.58%1.4M shares
ALLIANCEBERNSTEIN L.P.	1.56%1.37M shares

Percentages use 88.31M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys2$74.81M disclosed value

Sells (SEC code S)39$51.18M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Jun 25, 2026Form 4 · 10b5-1	Liu Brian Guan-ChyunDirector	BuyCommon Stock · indirect	371.1K	$66.87	$24.81M	1.89M
Jun 24, 2026Form 4 · 10b5-1	POST LEONARD EDirector	SellCommon Stock	5.0K	$70.00	$350.0K	0
Jun 22, 2026Form 4 · 10b5-1	POST LEONARD EDirector	SellCommon Stock	5.0K	$65.00	$325.0K	0
Jun 15, 2026Form 4 · 10b5-1	Mulay JamesDirector	SellCommon Stock	1.3K	$60.12	$78.8K	0
Jun 15, 2026Form 4 · 10b5-1	Mulay JamesDirector	SellCommon Stock	654	$60.12	$39.3K	0

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about CGON yet. Start the conversation.

Write the first post

CG Oncology, Inc. (CGON)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.